补充性静态和动态68Ga-FAPI-46 PET对原发性18F-FDG阴性肺部病变的诊断潜力
研究评估静态和动态68Ga-FAPI-46 PET在19例18F-FDG阴性肺部病变患者中的诊断潜力,并以24份贴壁型肺癌组织切片验证FAP表达。肺癌的68Ga-FAPI-46摄取、肿瘤背景比及68Ga-FAPI-46与18F-FDG比值均高于良性病变,动态曲线可区分两者;相对比值诊断效能最高。
要点
- 贴壁型肺癌组织免疫组化证实存在强FAP阳性癌相关成纤维细胞。
- 肺癌68Ga-FAPI-46摄取、肿瘤背景比及与18F-FDG比值均高于良性肺部病变。
- 68Ga-FAPI-46与18F-FDG的SUVmax和TBR相对比值区分肺癌与良性病变的灵敏度和特异度最高。
核心结论
- 68Ga-FAPI-46 PET是评估单发18F-FDG阴性肺部病变的有力新工具,可能优化该临床情境下的患者分层。
研究设计与样本
- 对本地组织库中24份贴壁型肺癌组织切片行苏木精-伊红染色和FAP免疫组化并肉眼分析。
- 19例患者在18F-FDG PET基础上根据个体临床指征加做静态和动态68Ga-FAPI-46 PET,之后接受手术或活检获组织学诊断。
主要发现
- FAP免疫组化证实贴壁型肺癌中存在强FAP阳性癌相关成纤维细胞。
- 肺癌的68Ga-FAPI-46摄取、肿瘤背景比及所有参数的68Ga-FAPI-46与18F-FDG比值均高于良性肺部病变。
- 动态分析显示肺癌与良性病变时间-活性曲线不同:肺癌典型表现为初始上升且斜率适度的曲线,良性病变为稳定下降曲线。
- 肺癌的达峰时间显著增加,斜率绝对值显著更小。
- 68Ga-FAPI-46与18F-FDG的SUVmax和TBR相对比值区分肺癌与良性肺部病变的灵敏度和特异度最高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET using 68Ga-labeled fibroblast activation protein (FAP) inhibitors (FAPIs) holds high potential for diagnostic imaging of various malignancies, including lung cancer (LC). However, 18F-FDG PET is still the clinical gold standard for LC imaging. Several subtypes of LC, especially lepidic LC, are frequently 18F-FDG PET-negative, which markedly hampers the assessment of single pulmonary lesions suggestive of LC. Here, we evaluated the diagnostic potential of static and dynamic 68Ga-FAPI-46 PET in the 18F-FDG-negative pulmonary lesions of 19 patients who underwent surgery or biopsy for histologic diagnosis after PET imaging. For target validation, FAP expression in lepidic LC was confirmed by FAP immunohistochemistry. Methods: Hematoxylin and eosin staining and FAP immunohistochemistry of 24 tissue sections of lepidic LC from the local tissue bank were performed and analyzed visually. Clinically, 19 patients underwent static and dynamic 68Ga-FAPI-46 PET in addition to 18F-FDG PET based on individual clinical indications. Static PET data of both examinations were analyzed by determining SUVmax, SUVmean, and tumor-to-background ratio (TBR) against the blood pool, as well as relative parameters (68Ga-FAPI-46 in relation to18F-FDG), of histologically confirmed LC and benign lesions. Time-activity curves and dynamic parameters (time to peak, slope, k 1, k 2, k 3, and k 4) were extracted from dynamic 68Ga-FAPI-46 PET data. The sensitivity and specificity of all parameters were analyzed by calculating receiver-operating-characteristic curves. Results: FAP immunohistochemistry confirmed the presence of strongly FAP-positive cancer-associated fibroblasts in lepidic LC. LC showed markedly elevated 68Ga-FAPI-46 uptake, higher TBRs, and higher 68Ga-FAPI-46-to-18F-FDG ratios for all parameters than did benign pulmonary lesions. Dynamic imaging analysis revealed differential time-activity curves for LC and benign pulmonary lesions: initially increasing time-activity curves with a decent slope were typical of LC, and steadily decreasing time-activity curve indicated benign pulmonary lesions, as was reflected by a significantly increased time to peak and significantly smaller absolute values of the slope for LC. Relative 68Ga-FAPI-46-to-18F-FDG ratios regarding SUVmax and TBR showed the highest sensitivity and specificity for the discrimination of LC from benign pulmonary lesions. Conclusion: 68Ga-FAPI-46 PET is a powerful new tool for the assessment of single 18F-FDG-negative pulmonary lesions and may optimize patient stratification in this clinical setting.
引用
- Röhrich M, Daum J, Gutjahr E, et al. Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG-Negative Pulmonary Lesions. J Nucl Med. 2024. PMID: 38604763. doi:10.2967/jnumed.123.267103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。